May 26, 2016—Sixty-nine stakeholders have submitted comments online to the Health Resources and Services Administration about its proposed rule setting standards for calculating 340B ceiling prices and implementing civil monetary penalties for drugmakers that knowingly and intentionally overcharge for 340B drugs. The drug industry is adamant that HRSA drop its 340B penny … [Read more...]
Projected Mega-Guidance Release Date Slips
New December timeframe not bindingMay 23, 2016—The projected release of the 340B program final mega-guidance has been pushed back from September to December 2016. … [Read more...]
340B Hospitals Serve Poor Patients Cancer Clinics Shun
Oncology groups that say 340B hospitals care more about money than low-income people made a revealing disclosure about their level of care for the poor during a hearing on Capitol Hill earlier this year. Dr. Debra Patt, a Texas private-practice oncologist, was testifying before the House Energy & Commerce Committee on May 17 about Medicare reimbursement. She was there on … [Read more...]
In Survey, Hospitals Describe How They Use 340B Savings to Help Patients
Group says curtailing drug discounts would devastate communities across AmericaMay 16, 2016—Safety-net hospitals rely heavily on 340B drug discount program savings to pay for free and discounted drugs, clinical services, and other vital benefits to vulnerable patients, a new report from the hospital group 340B Health concludes. … [Read more...]
340B Recertification for Title X Centers Begins May 11
Hospitals will go through process later this yearMay 10, 2016—Annual recertification of eligibility for 340B drug discounts for Title X family planning centers begins tomorrow, May 11 and ends on June 8, the Health Resources and Services Administration announced today. … [Read more...]
Genentech Owes 340B Providers Refunds for Overcharges
Notice covers 25 products sold between 1Q 2012 and 2Q 2013May 3, 2016—Genentech is offering 340B providers refunds for charges above statutorily defined ceiling prices on 25 products sold from the first quarter of 2012 to the second quarter of 2013. … [Read more...]
CMS Final Rule Addresses Using 340B Drugs in Medicaid Managed Care
States must establish procedures for preventing duplicate discountsApril 29, 2016—States must require Medicaid managed care organizations to establish procedures to exclude utilization data for drugs subject to 340B drug discounts from the utilization reports submitted to states for purposes of collecting Medicaid drug rebates, the Centers for Medicare & Medicaid Services says in a new final regulation. States also can opt instead to … [Read more...]